Please wait while the formulary information is being retrieved.
VECTIBIX (PANITUMUMAB)
- Wild-type KRAS and NRAS colorectal cancer
100 mg/5 mL (20 mg/mL) intravenous solution
- Dosage information is not available
400 mg/20 mL (20 mg/mL) intravenous solution
- Dosage information is not available
Wild-type KRAS and NRAS colorectal cancer
- Infuse 6 mg/kg over 60 minute(s) by intravenous route every 14 days for doses less than and/or equal to 1,000 mg
- Infuse 6 mg/kg over 60 minute(s) by intravenous route every 2 weeks for doses less than and/or equal to 1,000 mg
- Infuse 6 mg/kg over 90 minute(s) by intravenous route every 14 days for doses higher than 1,000 mg
- Infuse 6 mg/kg over 90 minute(s) by intravenous route every 2 weeks for doses higher than 1,000 mg
- natalizumab
- Tysabri
Contraindicated
- None
Severe
Moderate
- None
- Interstitial pneumonitis
- Lactating mother
- Necrotizing fasciitis
- Pulmonary fibrosis
Contraindicated
- Abscess
- Acute eruptions of skin
- Hypocalcemia
- Hypomagnesemia
- Pregnancy
- Sepsis
Severe
Moderate
- Keratitis
VECTIBIX (PANITUMUMAB)
- Wild-type KRAS and NRAS colorectal cancer
- Exfoliative dermatitis
- Hypomagnesemia
- Skin fissure
- Abdominal pain with cramps
- Constipation
- Cough
- Diarrhea
- Erythema
- Fatigue
- Nausea
- Paronychia
- Peripheral edema
- Pruritus of skin
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Bullous dermatitis
- Cellulitis
- Acne vulgaris
- Acneiform eruption
- Conjunctivitis
- Dermatitis due to sunlight
- Dry skin
- Hypertrichosis of eyelid eyelashes
- Nail disorders
- Paresthesia
- Stomatitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abscess
- Anaphylaxis
- Angioedema
- Bacterial sepsis
- Bronchospastic pulmonary disease
- Corneal ulcer
- Dermal necrosis
- Dyspnea
- Gastrointestinal obstruction
- Hypokalemia
- Hypotension
- Interstitial lung disease
- Keratitis
- Necrotizing fasciitis
- Pulmonary fibrosis
- Pulmonary thromboembolism
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
Less Severe
- Chills
- Eye tearing
- Eyelid erythema
- Fever
Contraindicated
None
Severe Precaution
Panitumumab
Limited studies suggest no anti-tumor effect in pediatrics.
- 1 Day – 18 Years
- Limited studies suggest no anti-tumor effect in pediatrics.
Management or Monitoring Precaution
None
Panitumumab
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Panitumumab
Serious adv events poss in infant; avoid bf during and 2 months after tx
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Serious adv events poss in infant; avoid bf during and 2 months after tx |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Panitumumab
General-Geriatric patients may experience a higher incidence of adverse drug reactions, particularly GI ADRs, when used in combination with other chemotherapeutic agents.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Panitumumab has caused very serious skin reactions, which can sometimes lead to serious infections. Tell your doctor right away if you develop any signs of a skin reaction, including acne, mild rash/itching, warmth/redness/swelling of the skin (including around the nails), dry/flaking skin, or skin sores (especially with pus). Get medical help right away if you develop any signs of a serious infection (such as sepsis), including fever, fast heartbeat, mental/mood changes (such as confusion), or signs of kidney problems (such as change in the amount of urine).
| Wild-type KRAS and NRAS colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| 0-9 | A-Z |
|---|---|
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
Formulary Reference Tool